# Immunogenicity and Safety of GSK Biologicals' Combined Measles-mumps-rubella Vaccine in Volunteers, Seven Years of Age and Older

> **NCT02058563** · PHASE3 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 996 (actual)

## Conditions studied

- Rubella
- Mumps
- Measles

## Interventions

- **BIOLOGICAL:** Priorix®
- **BIOLOGICAL:** Merck's M-M-R®II, Measles, Mumps, and Rubella Virus Vaccine

## Key facts

- **NCT ID:** NCT02058563
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-07-01
- **Primary completion:** 2015-05-24
- **Final completion:** 2015-09-17
- **Target enrollment:** 996 (ACTUAL)
- **Last updated:** 2018-06-06

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02058563

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02058563, "Immunogenicity and Safety of GSK Biologicals' Combined Measles-mumps-rubella Vaccine in Volunteers, Seven Years of Age and Older". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02058563. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*